From GlobeNewswire.: 2025-04-04 06:09:00

The molecular diagnostic for infectious diseases market is projected to reach US$ 17.61 billion by 2030, growing at a CAGR of 12.5%. Key players include F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., and more. Trends include AI integration, rapid testing, and decentralized diagnostics.

Thermo Fisher Scientific launches PCR kits for infectious disease detection in India, while Bruker introduces new solutions for Mycobacteria and Fungi IVD. The market is driven by technological advancements, early disease detection awareness, and personalized healthcare needs, with a focus on next-gen sequencing and point-of-care platforms.

Market segmentation for molecular diagnostics includes point-of-care vs. laboratory testing, human vs. vet testing, and application-based categories. Notably, the molecular diagnostic market is led by North America and expected to see rapid growth in Asia Pacific. The industry has seen immense growth post-COVID-19, emphasizing rapid, scalable diagnostics.

Advancements in molecular diagnostics technologies have revolutionized infectious disease diagnosis, with genetic and genomic studies enabling quick, accurate pathogen detection. As infectious diseases rise, demand for precise testing platforms surges, driving innovation in the sector. Various novel techniques have been developed to enhance diagnostic accuracy and speed.

The report highlights stakeholders like diagnostic manufacturers, healthcare providers, regulatory authorities, and more, navigating the evolving molecular diagnostics market landscape. With an increased incidence of infectious diseases globally and the shift towards personalized medicine, the sector is poised for continued innovation and growth.



Read more at GlobeNewswire.: Molecular Diagnostic for Infectious Diseases Market Size to